Procter & Gamble Health Ratios

Procter & Gamble Health Ltd Ratios

The Procter & Gamble Health Ltd Ratios page provides a complete fundamental analysis of Procter & Gamble Health Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Procter & Gamble Health Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Procter & Gamble Health Ltd (NSE: PGHL, BSE: 500126) is currently trading at ₹5086, with a market capitalization of ₹83.35B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Procter & Gamble Health Ltd remains a key stock for fundamental analysis using Procter & Gamble Health Ltd Ratios.

Procter & Gamble Health Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Procter & Gamble Health Ltd P/E ratio currently stands at 36.41, making it one of the most tracked metrics in Procter & Gamble Health Ltd Ratios.

Historically, the Procter & Gamble Health Ltd P/E ratio has shown strong fluctuations:

• 2024: 36.41
• 2023: 37.97
• 2022: 36.10
• 2021: 52.52
• 2020: 39.86

The decline in Procter & Gamble Health Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Procter & Gamble Health Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 15.90.

Historical P/B trend:

• 2024: 15.90
• 2023: 11.61
• 2022: 11.28
• 2021: 13.20

Procter & Gamble Health Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Procter & Gamble Health Ltd P/S ratio currently stands at 6.85, an important part of Procter & Gamble Health Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 6.85
• 2023: 7.09
• 2022: 6.25
• 2021: 9.21

A stable or declining Procter & Gamble Health Ltd P/S ratio indicates cautious market sentiment.

Procter & Gamble Health Ltd Price to Cash Flow Ratio (P/CF)

The Procter & Gamble Health Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 48.54.

Historical Procter & Gamble Health Ltd Price to Cash Flow Ratio:

• 2024: 48.54
• 2023: 34.83
• 2022: 38.74
• 2021: 35.13
• 2020: 22.81

The rising Procter & Gamble Health Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Procter & Gamble Health Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Procter & Gamble Health Ltd EV currently stands at ₹83.55B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 83.55B
• 2023: 82.85B
• 2022: 66.29B
• 2021: 88.24B

Procter & Gamble Health Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Procter & Gamble Health Ltd EV/EBITDA ratio is currently 19.32, a key metric in Procter & Gamble Health Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 19.32
• 2023: 25.18
• 2022: 24.47
• 2021: 34.89

Stable Procter & Gamble Health Ltd EV/EBITDA indicates balanced valuation.

Procter & Gamble Health Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Procter & Gamble Health Ltd D/E ratio is currently 0.01, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.01
• 2023: 0.02
• 2022: 0
• 2021: 0.01

Procter & Gamble Health Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Procter & Gamble Health Ltd ROE currently stands at 48.55%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 48.55
• 2023: 33.57
• 2022: 29.17
• 2021: 21.96

Procter & Gamble Health Ltd demonstrates strong profitability and efficient capital utilization.

Procter & Gamble Health Ltd Ratios Analysis Summary

The Procter & Gamble Health Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Procter & Gamble Health Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Procter & Gamble Health Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.